Kimberly F. Raab-Graham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kimberly F. Raab-Graham has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Farr Niere
Wake Forest School of Medicine, Winston Salem, NC USA
13 shared publications - Ayse Uneri
Wake Forest School of Medicine, Winston Salem, NC USA
6 shared publications - Chelcie F. Heaney
Wake Forest School of Medicine
6 shared publications Chelcie F. Heaney
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, United States
5 shared publicationsColin J. McArdle
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, United States
5 shared publicationsLuisa P. Cacheaux
Wake Forest School of Medicine
5 shared publications
Latest Publications
- Open Access
- 4 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4161-4175
17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats
Low 17β-estradiol (E2) in females of reproductive age, and marked E2 decline with menopause, contributes to heightened symptom severity in schizophrenia (i.e. cognitive dysfunction) and diminished response to antipsychotic medications. However, the underlying mechanisms are unknown. N-methyl-D-aspartate receptor (NMDAR) hypofunction contributes to the pathophysiology of schizophrenia, yet impact of E2 depletion on NMDAR function is not well characterized. Quantitative electroencephalography (qEEG), specifically gamma power, is a well-established functional readout of cortical activity that is elevated in patients with schizophrenia and is sensitive to alterations in NMDAR function. Using qEEG and touchscreen cognitive assessments, present studies investigated the effects of E2 on NMDAR function by administering MK-801 (NMDAR antagonist) to ovariectomized rats with or without E2 implants (Ovx+E and Ovx, respectively). Ovx rats were more sensitive to MK-801-induced elevations in gamma power and attentional impairments compared to Ovx+E rats. Further investigation revealed these effects were mediated by reduced synaptic GluN2A expression. Consistent with clinical reports, olanzapine (second-generation antipsychotic) was less effective in mitigating MK-801-induced elevations in gamma power in Ovx rats. Lastly, we examined antipsychotic-like activity of a Group II metabotropic glutamate receptor (mGlu2/3) positive allosteric modulator (PAM), SBI-0646535, as a novel therapeutic in E2-deprived conditions. SBI-0646535 reversed MK-801-induced elevations in gamma power regardless of E2 status. Collectively, these studies established a relationship between E2 deprivation and NMDAR function that is in part GluN2A-dependent, supporting the notion that E2 deprivation increases susceptibility to NMDAR hypofunction. This highlights the need to examine age/hormone-specific factors when considering antipsychotic response and designing novel pharmacotherapies.
- 4 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4161-4175
Open Access17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats
Low 17β-estradiol (E2) in females of reproductive age, and marked E2 decline with menopause, contributes to heightened symptom severity in schizophrenia (i.e. cognitive dysfunction) and diminished response to antipsychotic medications. However, the underlying mechanisms are unknown. N-methyl-D-aspartate receptor (NMDAR) hypofunction contributes to the pathophysiology of schizophrenia, yet impact of E2 depletion on NMDAR function is not well characterized. Quantitative electroencephalography (qEEG), specifically gamma power, is a well-established functional readout of cortical activity that is elevated in patients with schizophrenia and is sensitive to alterations in NMDAR function. Using qEEG and touchscreen cognitive assessments, present studies investigated the effects of E2 on NMDAR function by administering MK-801 (NMDAR antagonist) to ovariectomized rats with or without E2 implants (Ovx+E and Ovx, respectively). Ovx rats were more sensitive to MK-801-induced elevations in gamma power and attentional impairments compared to Ovx+E rats. Further investigation revealed these effects were mediated by reduced synaptic GluN2A expression. Consistent with clinical reports, olanzapine (second-generation antipsychotic) was less effective in mitigating MK-801-induced elevations in gamma power in Ovx rats. Lastly, we examined antipsychotic-like activity of a Group II metabotropic glutamate receptor (mGlu2/3) positive allosteric modulator (PAM), SBI-0646535, as a novel therapeutic in E2-deprived conditions. SBI-0646535 reversed MK-801-induced elevations in gamma power regardless of E2 status. Collectively, these studies established a relationship between E2 deprivation and NMDAR function that is in part GluN2A-dependent, supporting the notion that E2 deprivation increases susceptibility to NMDAR hypofunction. This highlights the need to examine age/hormone-specific factors when considering antipsychotic response and designing novel pharmacotherapies.
- 29 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (3) , 763-777
DJ-1-mediated repression of the RNA-binding protein FMRP is predicted to impact known Alzheimer's disease-related protein networks
Background: RNA-binding proteins (RBPs) modulate the synaptic proteome and are instrumental in maintaining synaptic homeostasis. Moreover, aberrant expression of an RBP in a disease state would have deleterious downstream effects on synaptic function. While many underlying mechanisms of synaptic dysfunction in Alzheimer's disease (AD) have been proposed, the contribution of RBPs has been relatively unexplored. Objective: To investigate alterations in RBP-messenger RNA (mRNA) interactions in AD, and its overall impact on the disease-related proteome. Methods: We first utilized RNA-immunoprecipitation to investigate interactions between RBP, DJ-1 (Parkinson's Disease protein 7) and target mRNAs in controls and AD. Surface Sensing of Translation – Proximity Ligation Assay (SUnSET-PLA) and western blotting additionally quantified alterations in mRNA translation and protein expression of DJ-1 targets. Finally, we utilized an unbiased bioinformatic approach that connects AD-related pathways to two RBPs, DJ-1 and FMRP (Fragile X messenger ribonucleoprotein 1). Results: We find that oligomeric DJ-1 in AD donor synapses were less dynamic in their ability to bind and unbind mRNA compared to synapses from cognitively unimpaired, neuropathologically-verified controls. Furthermore, we find that DJ-1 associates with the mRNA coding for FMRP, Fmr1 , leading to its reduced synaptic expression in AD. Through the construction of protein-protein interaction networks, aberrant expression of DJ-1 and FMRP are predicted to lead to the upregulation of key AD-related pathways, such as thyroid hormone stimulating pathway, autophagy, and ubiquitin mediated proteolysis. Conclusions: DJ-1 and FMRP are novel targets that may restore established neurobiological mechanisms underlying AD.
- 29 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (3) , 763-777
DJ-1-mediated repression of the RNA-binding protein FMRP is predicted to impact known Alzheimer's disease-related protein networks
Background: RNA-binding proteins (RBPs) modulate the synaptic proteome and are instrumental in maintaining synaptic homeostasis. Moreover, aberrant expression of an RBP in a disease state would have deleterious downstream effects on synaptic function. While many underlying mechanisms of synaptic dysfunction in Alzheimer's disease (AD) have been proposed, the contribution of RBPs has been relatively unexplored. Objective: To investigate alterations in RBP-messenger RNA (mRNA) interactions in AD, and its overall impact on the disease-related proteome. Methods: We first utilized RNA-immunoprecipitation to investigate interactions between RBP, DJ-1 (Parkinson's Disease protein 7) and target mRNAs in controls and AD. Surface Sensing of Translation – Proximity Ligation Assay (SUnSET-PLA) and western blotting additionally quantified alterations in mRNA translation and protein expression of DJ-1 targets. Finally, we utilized an unbiased bioinformatic approach that connects AD-related pathways to two RBPs, DJ-1 and FMRP (Fragile X messenger ribonucleoprotein 1). Results: We find that oligomeric DJ-1 in AD donor synapses were less dynamic in their ability to bind and unbind mRNA compared to synapses from cognitively unimpaired, neuropathologically-verified controls. Furthermore, we find that DJ-1 associates with the mRNA coding for FMRP, Fmr1 , leading to its reduced synaptic expression in AD. Through the construction of protein-protein interaction networks, aberrant expression of DJ-1 and FMRP are predicted to lead to the upregulation of key AD-related pathways, such as thyroid hormone stimulating pathway, autophagy, and ubiquitin mediated proteolysis. Conclusions: DJ-1 and FMRP are novel targets that may restore established neurobiological mechanisms underlying AD.
- Open Access
- 26 August 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1404884
Potential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex
Tuberous Sclerosis Complex (TSC) is a lynchpin disorder, as it results in overactive mammalian target of rapamycin (mTOR) signaling, which has been implicated in a multitude of disease states. TSC is an autosomal dominant disease where 90% of affected individuals develop epilepsy. Epilepsy results from aberrant neuronal excitability that leads to recurring seizures. Under neurotypical conditions, the coordinated activity of voltage-gated ion channels keep neurons operating in an optimal range, thus providing network stability. Interestingly, loss or gain of function mutations in voltage-gated potassium, sodium, or calcium channels leads to altered excitability and seizures. To date, little is known about voltage-gated ion channel expression and function in TSC. However, data is beginning to emerge on how mTOR signaling regulates voltage-gated ion channel expression in neurons. Herein, we provide a comprehensive review of the literature describing common seizure types in patients with TSC, and suggest possible parallels between acquired epilepsies with known voltage-gated ion channel dysfunction. Furthermore, we discuss possible links toward mTOR regulation of voltage-gated ion channels expression and channel kinetics and the underlying epileptic manifestations in patients with TSC.
- 26 August 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1404884
Open AccessPotential roles of voltage-gated ion channel disruption in Tuberous Sclerosis Complex
Tuberous Sclerosis Complex (TSC) is a lynchpin disorder, as it results in overactive mammalian target of rapamycin (mTOR) signaling, which has been implicated in a multitude of disease states. TSC is an autosomal dominant disease where 90% of affected individuals develop epilepsy. Epilepsy results from aberrant neuronal excitability that leads to recurring seizures. Under neurotypical conditions, the coordinated activity of voltage-gated ion channels keep neurons operating in an optimal range, thus providing network stability. Interestingly, loss or gain of function mutations in voltage-gated potassium, sodium, or calcium channels leads to altered excitability and seizures. To date, little is known about voltage-gated ion channel expression and function in TSC. However, data is beginning to emerge on how mTOR signaling regulates voltage-gated ion channel expression in neurons. Herein, we provide a comprehensive review of the literature describing common seizure types in patients with TSC, and suggest possible parallels between acquired epilepsies with known voltage-gated ion channel dysfunction. Furthermore, we discuss possible links toward mTOR regulation of voltage-gated ion channels expression and channel kinetics and the underlying epileptic manifestations in patients with TSC.
- Open Access
- 10 January 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1296527
A paradoxical switch: the implications of excitatory GABAergic signaling in neurological disorders
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. In the mature brain, inhibitory GABAergic signaling is critical in maintaining neuronal homeostasis and vital human behaviors such as cognition, emotion, and motivation. While classically known to inhibit neuronal function under physiological conditions, previous research indicates a paradoxical switch from inhibitory to excitatory GABAergic signaling that is implicated in several neurological disorders. Various mechanisms have been proposed to contribute to the excitatory switch such as chloride ion dyshomeostasis, alterations in inhibitory receptor expression, and modifications in GABAergic synaptic plasticity. Of note, the hypothesized mechanisms underlying excitatory GABAergic signaling are highlighted in a number of neurodevelopmental, substance use, stress, and neurodegenerative disorders. Herein, we present an updated review discussing the presence of excitatory GABAergic signaling in various neurological disorders, and their potential contributions towards disease pathology.
- 10 January 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1296527
Open AccessA paradoxical switch: the implications of excitatory GABAergic signaling in neurological disorders
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. In the mature brain, inhibitory GABAergic signaling is critical in maintaining neuronal homeostasis and vital human behaviors such as cognition, emotion, and motivation. While classically known to inhibit neuronal function under physiological conditions, previous research indicates a paradoxical switch from inhibitory to excitatory GABAergic signaling that is implicated in several neurological disorders. Various mechanisms have been proposed to contribute to the excitatory switch such as chloride ion dyshomeostasis, alterations in inhibitory receptor expression, and modifications in GABAergic synaptic plasticity. Of note, the hypothesized mechanisms underlying excitatory GABAergic signaling are highlighted in a number of neurodevelopmental, substance use, stress, and neurodegenerative disorders. Herein, we present an updated review discussing the presence of excitatory GABAergic signaling in various neurological disorders, and their potential contributions towards disease pathology.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Exaggerated translational repression of FMRP in AD synapses
Background: Alzheimer’s Disease (AD) is a progressive cognitive disorder where synapse loss has been well documented. Identifying and restoring molecular targets that are involved in synapse loss is crucial in restoring balanced synaptic function and communication. FMRP is an RNA‐binding protein that is essential protein for synapse formation and stability, and is understudied in AD. Understanding how FMRP may be dysregulated at the synaptic level in AD is integral in developing treatments for AD.Method: RNA‐immunoprecipitation of DJ‐1 was performed to detect whether DJ‐1 associates with the mRNA coding for FMRP. Synaptoneurosomes and postsynaptic densities we isolated from AD rodent model APP/PS1deltaE9 and postmortem human AD patients, as well as from appropriate controls, and performed Western blotting to analyze FMRP protein expression. SUnSET‐PLA assay was utilized to determine de novo synthesis of FMRP in DJ‐1 overexpression.Result: DJ‐1, which is an RNA‐binding protein that is overexpressed in AD synapses, associates with Fmr1, the mRNA coding for the protein FMRP. FMRP expression is decreased in AD synapses, as well as postsynaptic densities. When DJ‐1 is overexpressed in WT cultures, there is less newly synthesized FMRP.Conclusion: Here, we show that DJ‐1 associates with Fmr1, which codes for another RNA‐binding protein, FMRP. DJ‐1 and FMRP are aberrantly expressed in AD synapses. DJ‐1 is overexpressed in AD synapses while FMRP is reduced. Furthermore, when DJ‐1 is overexpressed in WT cultures, FMRP synthesis is reduced, suggesting that DJ‐1 is a translational repressor of FMRP. Therefore, the reduction of FMRP in AD synapses are due to overexpression of DJ‐1, and the rescue of FMRP expression could potentially rescue synaptic loss in AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessExaggerated translational repression of FMRP in AD synapses
Background: Alzheimer’s Disease (AD) is a progressive cognitive disorder where synapse loss has been well documented. Identifying and restoring molecular targets that are involved in synapse loss is crucial in restoring balanced synaptic function and communication. FMRP is an RNA‐binding protein that is essential protein for synapse formation and stability, and is understudied in AD. Understanding how FMRP may be dysregulated at the synaptic level in AD is integral in developing treatments for AD.Method: RNA‐immunoprecipitation of DJ‐1 was performed to detect whether DJ‐1 associates with the mRNA coding for FMRP. Synaptoneurosomes and postsynaptic densities we isolated from AD rodent model APP/PS1deltaE9 and postmortem human AD patients, as well as from appropriate controls, and performed Western blotting to analyze FMRP protein expression. SUnSET‐PLA assay was utilized to determine de novo synthesis of FMRP in DJ‐1 overexpression.Result: DJ‐1, which is an RNA‐binding protein that is overexpressed in AD synapses, associates with Fmr1, the mRNA coding for the protein FMRP. FMRP expression is decreased in AD synapses, as well as postsynaptic densities. When DJ‐1 is overexpressed in WT cultures, there is less newly synthesized FMRP.Conclusion: Here, we show that DJ‐1 associates with Fmr1, which codes for another RNA‐binding protein, FMRP. DJ‐1 and FMRP are aberrantly expressed in AD synapses. DJ‐1 is overexpressed in AD synapses while FMRP is reduced. Furthermore, when DJ‐1 is overexpressed in WT cultures, FMRP synthesis is reduced, suggesting that DJ‐1 is a translational repressor of FMRP. Therefore, the reduction of FMRP in AD synapses are due to overexpression of DJ‐1, and the rescue of FMRP expression could potentially rescue synaptic loss in AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
GABAB receptor activation promotes synaptic resilience in Alzheimer’s disease
Background: Hyperexcitability and glutamate excitotoxicity are the primary contributors towards synapse loss in Alzheimer’s disease (AD). The goal of this project is to examine how other neurotransmitter systems, such as the inhibitory GABAergic system, are responding to hyperexcitability in AD. Therefore, we examined the role of metabotropic GABAB receptors (GABABRs) towards synapse loss.Methods: Primary hippocampal neurons were cultured from both wildtype (WT) and transgenic APP/PS1 mice. In addition, treatment of non‐transgenic hippocampal neurons with Aβ oligomers (500nM) were used as another model of AD‐related pathology. Immunocytochemistry was used to determine the dendric expression of GABAB1R and GABAB2R, the two principal subunits of GABABRs. To examine changes in GABABR function, a calcium imaging protocol was utilized to quantify changes in calcium florescence following GABABR activation with baclofen (50μM). To understand whether GABABR activation is protective against synaptic loss in AD, APP/PS1 hippocampal neurons were treated with 50μM baclofen (GABABR agonist), 100μM CGP35348 (GABABR antagonist), or vehicle. This study used both colocalization of presynaptic (Synapsin‐1) and postsynaptic (PSD95) markers as well as a novel method, DetectSyn, to quantify changes in synaptic density.Results: Dendritic GABAB1R and GABAB2R expression is upregulated in APP/PS1 hippocampal neurons as compared to WT. Non‐transgenic neurons treated with Aβ‐oligomers also show upregulations in GABAB2R, with no changes in GABAB1R. Treating WT neurons with baclofen resulted in an approximate 10% decrease in calcium florescence. The same treatment applied to APP/PS1 neurons resulted in a significantly greater decrease (∼40%) in calcium florescence. Activating GABABRs in APP/PS1 neurons increased synaptic density as compared to vehicle treated neurons. This was indicated by a greater Pearson’s coefficient between Synapsin‐1 and PSD95, as well as a greater number of DetectSyn‐PLA puncta. Antagonizing GABABRs in APP/PS1 neurons failed to rescue synaptic density (no changes in Pearson’s coefficient/DetectSyn‐PLA puncta) when compared to vehicle treated neurons.Conclusions: Under pathological conditions, upregulation and activation of GABABRs serves as a potential mechanism to combat against hyperexcitability, therefore preventing hippocampal synaptic loss in AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessGABAB receptor activation promotes synaptic resilience in Alzheimer’s disease
Background: Hyperexcitability and glutamate excitotoxicity are the primary contributors towards synapse loss in Alzheimer’s disease (AD). The goal of this project is to examine how other neurotransmitter systems, such as the inhibitory GABAergic system, are responding to hyperexcitability in AD. Therefore, we examined the role of metabotropic GABAB receptors (GABABRs) towards synapse loss.Methods: Primary hippocampal neurons were cultured from both wildtype (WT) and transgenic APP/PS1 mice. In addition, treatment of non‐transgenic hippocampal neurons with Aβ oligomers (500nM) were used as another model of AD‐related pathology. Immunocytochemistry was used to determine the dendric expression of GABAB1R and GABAB2R, the two principal subunits of GABABRs. To examine changes in GABABR function, a calcium imaging protocol was utilized to quantify changes in calcium florescence following GABABR activation with baclofen (50μM). To understand whether GABABR activation is protective against synaptic loss in AD, APP/PS1 hippocampal neurons were treated with 50μM baclofen (GABABR agonist), 100μM CGP35348 (GABABR antagonist), or vehicle. This study used both colocalization of presynaptic (Synapsin‐1) and postsynaptic (PSD95) markers as well as a novel method, DetectSyn, to quantify changes in synaptic density.Results: Dendritic GABAB1R and GABAB2R expression is upregulated in APP/PS1 hippocampal neurons as compared to WT. Non‐transgenic neurons treated with Aβ‐oligomers also show upregulations in GABAB2R, with no changes in GABAB1R. Treating WT neurons with baclofen resulted in an approximate 10% decrease in calcium florescence. The same treatment applied to APP/PS1 neurons resulted in a significantly greater decrease (∼40%) in calcium florescence. Activating GABABRs in APP/PS1 neurons increased synaptic density as compared to vehicle treated neurons. This was indicated by a greater Pearson’s coefficient between Synapsin‐1 and PSD95, as well as a greater number of DetectSyn‐PLA puncta. Antagonizing GABABRs in APP/PS1 neurons failed to rescue synaptic density (no changes in Pearson’s coefficient/DetectSyn‐PLA puncta) when compared to vehicle treated neurons.Conclusions: Under pathological conditions, upregulation and activation of GABABRs serves as a potential mechanism to combat against hyperexcitability, therefore preventing hippocampal synaptic loss in AD.
- Open Access
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Aberrant DJ-1 expression underlies L-type calcium channel hypoactivity in dendrites in tuberous sclerosis complex and Alzheimer’s disease
L-type voltage-gated calcium (Ca 2+ ) channels (L-VGCC) dysfunction is implicated in several neurological and psychiatric diseases. While a popular therapeutic target, it is unknown whether molecular mechanisms leading to disrupted L-VGCC across neurodegenerative disorders are conserved. Importantly, L-VGCC integrate synaptic signals to facilitate a plethora of cellular mechanisms; however, mechanisms that regulate L-VGCC channel density and subcellular compartmentalization are understudied. Herein, we report that in disease models with overactive mammalian target of rapamycin complex 1 (mTORC1) signaling (or mTORopathies), deficits in dendritic L-VGCC activity are associated with increased expression of the RNA-binding protein (RBP) Parkinsonism-associated deglycase (DJ-1). DJ-1 binds the mRNA coding for the alpha and auxiliary Ca 2+ channel subunits Ca V 1.2 and α2δ2, and represses their mRNA translation, only in the disease states, specifically preclinical models of tuberous sclerosis complex (TSC) and Alzheimer’s disease (AD). In agreement, DJ-1-mediated repression of Ca V 1.2/α2δ2 protein synthesis in dendrites is exaggerated in mouse models of AD and TSC, resulting in deficits in dendritic L-VGCC calcium activity. Finding of DJ-1-regulated L-VGCC activity in dendrites in TSC and AD provides a unique signaling pathway that can be targeted in clinical mTORopathies.
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Open AccessAberrant DJ-1 expression underlies L-type calcium channel hypoactivity in dendrites in tuberous sclerosis complex and Alzheimer’s disease
L-type voltage-gated calcium (Ca 2+ ) channels (L-VGCC) dysfunction is implicated in several neurological and psychiatric diseases. While a popular therapeutic target, it is unknown whether molecular mechanisms leading to disrupted L-VGCC across neurodegenerative disorders are conserved. Importantly, L-VGCC integrate synaptic signals to facilitate a plethora of cellular mechanisms; however, mechanisms that regulate L-VGCC channel density and subcellular compartmentalization are understudied. Herein, we report that in disease models with overactive mammalian target of rapamycin complex 1 (mTORC1) signaling (or mTORopathies), deficits in dendritic L-VGCC activity are associated with increased expression of the RNA-binding protein (RBP) Parkinsonism-associated deglycase (DJ-1). DJ-1 binds the mRNA coding for the alpha and auxiliary Ca 2+ channel subunits Ca V 1.2 and α2δ2, and represses their mRNA translation, only in the disease states, specifically preclinical models of tuberous sclerosis complex (TSC) and Alzheimer’s disease (AD). In agreement, DJ-1-mediated repression of Ca V 1.2/α2δ2 protein synthesis in dendrites is exaggerated in mouse models of AD and TSC, resulting in deficits in dendritic L-VGCC calcium activity. Finding of DJ-1-regulated L-VGCC activity in dendrites in TSC and AD provides a unique signaling pathway that can be targeted in clinical mTORopathies.
- Open Access
- 10 November 2022
- Published by Society for Neuroscience in eneuro
- Vol. 9 (6)
Chronic Intermittent Ethanol Exposure Dysregulates Nucleus Basalis Magnocellularis Afferents in the Basolateral Amygdala
Nucleus basalis magnocellularis (NBM) cholinergic projections to the basolateral amygdala (BLA) regulate the acquisition and consolidation of fear-like and anxiety-like behaviors. However, it is unclear whether the alterations in the NBM-BLA circuit promote negative affect during ethanol withdrawal (WD). Therefore, we performedex vivowhole-cell patch-clamp electrophysiology in both the NBM and the BLA of male Sprague Dawley rats following 10 d of chronic intermittent ethanol (CIE) exposure and 24 h of WD. We found that CIE exposure and withdrawal enhanced the neuronal excitability of NBM putative “cholinergic” neurons. We subsequently used optogenetics to directly manipulate NBM terminal activity within the BLA and measure cholinergic modulation of glutamatergic afferents and BLA pyramidal neurons. Our findings indicate that CIE and withdrawal upregulate NBM cholinergic facilitation of glutamate release via activation of presynaptic nicotinic acetylcholine receptors (AChRs). Ethanol withdrawal-induced increases in NBM terminal activity also enhance BLA pyramidal neuron firing. Collectively, our results provide a novel characterization of the NBM-BLA circuit and suggest that CIE-dependent modifications to NBM afferents enhance BLA pyramidal neuron activity during ethanol withdrawal.
- 10 November 2022
- Published by Society for Neuroscience in eneuro
- Vol. 9 (6)
Open AccessChronic Intermittent Ethanol Exposure Dysregulates Nucleus Basalis Magnocellularis Afferents in the Basolateral Amygdala
Nucleus basalis magnocellularis (NBM) cholinergic projections to the basolateral amygdala (BLA) regulate the acquisition and consolidation of fear-like and anxiety-like behaviors. However, it is unclear whether the alterations in the NBM-BLA circuit promote negative affect during ethanol withdrawal (WD). Therefore, we performedex vivowhole-cell patch-clamp electrophysiology in both the NBM and the BLA of male Sprague Dawley rats following 10 d of chronic intermittent ethanol (CIE) exposure and 24 h of WD. We found that CIE exposure and withdrawal enhanced the neuronal excitability of NBM putative “cholinergic” neurons. We subsequently used optogenetics to directly manipulate NBM terminal activity within the BLA and measure cholinergic modulation of glutamatergic afferents and BLA pyramidal neurons. Our findings indicate that CIE and withdrawal upregulate NBM cholinergic facilitation of glutamate release via activation of presynaptic nicotinic acetylcholine receptors (AChRs). Ethanol withdrawal-induced increases in NBM terminal activity also enhance BLA pyramidal neuron firing. Collectively, our results provide a novel characterization of the NBM-BLA circuit and suggest that CIE-dependent modifications to NBM afferents enhance BLA pyramidal neuron activity during ethanol withdrawal.
- 22 July 2022
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 185,p. e63139
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Synapses are the site of communication between neurons. Neuronal circuit strength is related to synaptic density, and the breakdown of synapses is characteristic of disease states like major depressive disorder (MDD) and Alzheimer's disease. Traditional techniques to investigate synapse numbers include genetic expression of fluorescent markers (e.g., green fluorescent protein (GFP)), dyes that fill a neuron (e.g., carbocyanine dye, DiI), and immunofluorescent detection of spine markers (e.g., postsynaptic density 95 (PSD95)). A major caveat to these proxy techniques is that they only identify postsynaptic changes. Yet, a synapse is a connection between a presynaptic terminal and a postsynaptic spine. The gold standard for measuring synapse formation/elimination requires time-consuming electron microscopy or array tomography techniques. These techniques require specialized training and costly equipment. Further, only a limited number of neurons can be assessed and are used to represent changes to an entire brain region. DetectSyn is a rapid fluorescent technique that identifies changes to synapse formation or elimination due to a disease state or drug activity. DetectSyn utilizes a rapid proximity ligation assay to detect juxtaposed pre- and postsynaptic proteins and standard fluorescent microscopy, a technique readily available to most laboratories. Fluorescent detection of the resulting puncta allows for quick and unbiased analysis of experiments. DetectSyn provides more representative results than electron microscopy because larger areas can be analyzed than a limited number of fluorescent neurons. Moreover, DetectSyn works for in vitro cultured neurons and fixed tissue slices. Finally, a method is provided to analyze the data collected from this technique. Overall, DetectSyn offers a procedure for detecting relative changes in synapse density across treatments or disease states and is more accessible than traditional techniques.
- 22 July 2022
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 185,p. e63139
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Synapses are the site of communication between neurons. Neuronal circuit strength is related to synaptic density, and the breakdown of synapses is characteristic of disease states like major depressive disorder (MDD) and Alzheimer's disease. Traditional techniques to investigate synapse numbers include genetic expression of fluorescent markers (e.g., green fluorescent protein (GFP)), dyes that fill a neuron (e.g., carbocyanine dye, DiI), and immunofluorescent detection of spine markers (e.g., postsynaptic density 95 (PSD95)). A major caveat to these proxy techniques is that they only identify postsynaptic changes. Yet, a synapse is a connection between a presynaptic terminal and a postsynaptic spine. The gold standard for measuring synapse formation/elimination requires time-consuming electron microscopy or array tomography techniques. These techniques require specialized training and costly equipment. Further, only a limited number of neurons can be assessed and are used to represent changes to an entire brain region. DetectSyn is a rapid fluorescent technique that identifies changes to synapse formation or elimination due to a disease state or drug activity. DetectSyn utilizes a rapid proximity ligation assay to detect juxtaposed pre- and postsynaptic proteins and standard fluorescent microscopy, a technique readily available to most laboratories. Fluorescent detection of the resulting puncta allows for quick and unbiased analysis of experiments. DetectSyn provides more representative results than electron microscopy because larger areas can be analyzed than a limited number of fluorescent neurons. Moreover, DetectSyn works for in vitro cultured neurons and fixed tissue slices. Finally, a method is provided to analyze the data collected from this technique. Overall, DetectSyn offers a procedure for detecting relative changes in synapse density across treatments or disease states and is more accessible than traditional techniques.
- 22 July 2022
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 185,p. e63139
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Synapses are the site of communication between neurons. Neuronal circuit strength is related to synaptic density, and the breakdown of synapses is characteristic of disease states like major depressive disorder (MDD) and Alzheimer's disease. Traditional techniques to investigate synapse numbers include genetic expression of fluorescent markers (e.g., green fluorescent protein (GFP)), dyes that fill a neuron (e.g., carbocyanine dye, DiI), and immunofluorescent detection of spine markers (e.g., postsynaptic density 95 (PSD95)). A major caveat to these proxy techniques is that they only identify postsynaptic changes. Yet, a synapse is a connection between a presynaptic terminal and a postsynaptic spine. The gold standard for measuring synapse formation/elimination requires time-consuming electron microscopy or array tomography techniques. These techniques require specialized training and costly equipment. Further, only a limited number of neurons can be assessed and are used to represent changes to an entire brain region. DetectSyn is a rapid fluorescent technique that identifies changes to synapse formation or elimination due to a disease state or drug activity. DetectSyn utilizes a rapid proximity ligation assay to detect juxtaposed pre- and postsynaptic proteins and standard fluorescent microscopy, a technique readily available to most laboratories. Fluorescent detection of the resulting puncta allows for quick and unbiased analysis of experiments. DetectSyn provides more representative results than electron microscopy because larger areas can be analyzed than a limited number of fluorescent neurons. Moreover, DetectSyn works for in vitro cultured neurons and fixed tissue slices. Finally, a method is provided to analyze the data collected from this technique. Overall, DetectSyn offers a procedure for detecting relative changes in synapse density across treatments or disease states and is more accessible than traditional techniques.
- 22 July 2022
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 185,p. e63139
DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Synapses are the site of communication between neurons. Neuronal circuit strength is related to synaptic density, and the breakdown of synapses is characteristic of disease states like major depressive disorder (MDD) and Alzheimer's disease. Traditional techniques to investigate synapse numbers include genetic expression of fluorescent markers (e.g., green fluorescent protein (GFP)), dyes that fill a neuron (e.g., carbocyanine dye, DiI), and immunofluorescent detection of spine markers (e.g., postsynaptic density 95 (PSD95)). A major caveat to these proxy techniques is that they only identify postsynaptic changes. Yet, a synapse is a connection between a presynaptic terminal and a postsynaptic spine. The gold standard for measuring synapse formation/elimination requires time-consuming electron microscopy or array tomography techniques. These techniques require specialized training and costly equipment. Further, only a limited number of neurons can be assessed and are used to represent changes to an entire brain region. DetectSyn is a rapid fluorescent technique that identifies changes to synapse formation or elimination due to a disease state or drug activity. DetectSyn utilizes a rapid proximity ligation assay to detect juxtaposed pre- and postsynaptic proteins and standard fluorescent microscopy, a technique readily available to most laboratories. Fluorescent detection of the resulting puncta allows for quick and unbiased analysis of experiments. DetectSyn provides more representative results than electron microscopy because larger areas can be analyzed than a limited number of fluorescent neurons. Moreover, DetectSyn works for in vitro cultured neurons and fixed tissue slices. Finally, a method is provided to analyze the data collected from this technique. Overall, DetectSyn offers a procedure for detecting relative changes in synapse density across treatments or disease states and is more accessible than traditional techniques.